{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:15:07Z","timestamp":1783185307234,"version":"3.54.6"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002878","name":"Consejer\u00eda de Econom\u00eda, Innovaci\u00f3n, Ciencia y Empleo, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["P11-CTS-6317"],"award-info":[{"award-number":["P11-CTS-6317"]}],"id":[{"id":"10.13039\/501100002878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["CP15\/01358"],"award-info":[{"award-number":["CP15\/01358"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI13\/01744"],"award-info":[{"award-number":["PI13\/01744"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01306"],"award-info":[{"award-number":["PI16\/01306"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.eimce.2020.06.019","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T19:19:37Z","timestamp":1641237577000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of the immune response modification by lysophosphatidylcholine in the efficacy of antibiotic therapy of experimental models of peritoneal sepsis and pneumonia by Pseudomonas aeruginosa: LPC therapeutic effect in combined therapy"],"prefix":"10.1016","volume":"40","author":[{"given":"Raquel","family":"Parra-Mill\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel E.","family":"Jim\u00e9nez-Mej\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Ayerbe-Algaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Dom\u00ednguez-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caridad","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"P\u00e9rez del Palacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer\u00f3nimo","family":"Pach\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younes","family":"Smani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2020.06.019_bib0185","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/2049-632X.12033","article-title":"Pseudomonas aeruginosa: new insights into pathogenesis and host defenses","volume":"67","author":"Gellatly","year":"2013","journal-title":"Pathog Dis"},{"key":"10.1016\/j.eimce.2020.06.019_bib0190","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/377200","article-title":"Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome","volume":"37","author":"Kang","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2020.06.019_bib0195","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1001\/archinte.1996.00440170139015","article-title":"Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes","volume":"156","author":"Vidal","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimce.2020.06.019_bib0200","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/S0140-6736(03)13644-6","article-title":"Nosocomial infections in adult intensive-care units","volume":"9374","author":"Vincent","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.eimce.2020.06.019_bib0205","series-title":"Annual epidemiological report 2014. Antimicrobial resistance and healthcare-associated infections","author":"European Centre for Disease Prevention and Control","year":"2014"},{"key":"10.1016\/j.eimce.2020.06.019_bib0210","first-page":"12","article-title":"Multi-drug resistant Pseudomonas aeruginosa: a threat of nosocomial infections in tertiary care hospitals","volume":"65","author":"Ali","year":"2015","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.eimce.2020.06.019_bib0215","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1186\/s13054-015-0926-5","article-title":"An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance","volume":"19","author":"Micek","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.eimce.2020.06.019_bib0220","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/phar.1636","article-title":"Infections caused by resistant gram-negative bacteria: epidemiology and management","volume":"35","author":"Kaye","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eimce.2020.06.019_bib0225","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/dkp201","article-title":"Update on the treatment of Pseudomonas aeruginosa pneumonia","volume":"64","author":"El Solh","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2020.06.019_bib0230","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/mdr.2010.0170","article-title":"Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome","volume":"17","author":"Joo","year":"2011","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.eimce.2020.06.019_bib0235","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimce.2020.06.019_bib0240","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1073\/pnas.85.8.2805","article-title":"Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis","volume":"85","author":"Quinn","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.eimce.2020.06.019_bib0245","doi-asserted-by":"crossref","first-page":"31430","DOI":"10.1016\/S0021-9258(18)31712-5","article-title":"Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages","volume":"269","author":"Sakai","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.eimce.2020.06.019_bib0250","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1073\/pnas.89.14.6447","article-title":"Role of lysophosphatidylcholine in T-lymphocyte aactivation: involvment of phospholipase A in signal transduction through protein kinase C","volume":"89","author":"Asaoka","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.eimce.2020.06.019_bib0255","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0014-5793(98)01526-9","article-title":"Lysophosphatidylcholine generates superoxide anions through activation of phosphatidylinositol 3-kinase in human neutrophils","volume":"441","author":"Nishioka","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.eimce.2020.06.019_bib0260","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nm989","article-title":"Therapeutic effects of lysophosphatidylcholine in experimental sepsis","volume":"10","author":"Yan","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.eimce.2020.06.019_bib0265","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1126\/science.1061781","article-title":"Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A","volume":"293","author":"Kabarowski","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.eimce.2020.06.019_bib0270","doi-asserted-by":"crossref","first-page":"41325","DOI":"10.1074\/jbc.M008057200","article-title":"Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4","volume":"276","author":"Zhu","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.eimce.2020.06.019_bib0275","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1128\/IAI.00683-08","article-title":"Trypanosoma cruzi infection is enhanced by vector saliva through immunosuppressant mechanisms mediated by lysophosphatidylcholine","volume":"76","author":"Mesquita","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.eimce.2020.06.019_bib0280","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1073\/pnas.2536801100","article-title":"T Cell chemotaxis to lysophosphatidylcholine through the G2A receptor","volume":"101","author":"Radu","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.eimce.2020.06.019_bib0285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1568005310303010023","article-title":"Unfolding the pathophysiological role of bioactive lysophospholipids","volume":"3","author":"Xu","year":"2003","journal-title":"Curr Drug Targets Immun Endocr Metabol Disord"},{"key":"10.1016\/j.eimce.2020.06.019_bib0290","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1128\/AAC.04986-14","article-title":"Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii","volume":"59","author":"Smani","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2020.06.019_bib0295","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1128\/AAC.02708-15","article-title":"Efficacy of lysophosphatidylcholine in combination with antimicrobial agents against Acinetobacter baumannii in experimental murine peritoneal sepsis and pneumonia models","volume":"60","author":"Parra Mill\u00e1n","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2020.06.019_bib0300","first-page":"89","article-title":"Antimicrobial effects of lysophosphatidylcholine on methicillin-resistant Staphylococcus aureus","volume":"4","author":"Miyazaki","year":"2017","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.eimce.2020.06.019_bib0305","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.05991-11","article-title":"Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections","volume":"56","author":"Pe\u00f1a","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2020.06.019_bib0310","series-title":"Performance standards for antimicrobial susceptibility testing. Twenty-fourth informational supplement. Document M100-S24","author":"Clinical and Laboratory Standards Institute","year":"2014"},{"key":"10.1016\/j.eimce.2020.06.019_bib0315","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03695.x","article-title":"In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii","volume":"18","author":"Smani","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimce.2020.06.019_bib0320","series-title":"Guide for the care and use of laboratory animals: eighth edition","author":"National Research Council","year":"2011"},{"key":"10.1016\/j.eimce.2020.06.019_bib0325","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jpba.2008.06.012","article-title":"Simultaneous determination of vancomycin and ceftazidime in cerebrospinal fluid in craniotomy patients by high-performance liquid chromatography","volume":"48","author":"Ye","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.eimce.2020.06.019_bib0330","series-title":"PK functions for microsoft excel","author":"Usansky","year":"2012"},{"key":"10.1016\/j.eimce.2020.06.019_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2020.06.019_bib0340","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jac\/dks343","article-title":"Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: In vivo antimicrobial activity and impact on host inflammatory response","volume":"68","author":"Jacqueline","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2020.06.019_bib0345","first-page":"120","article-title":"Modeling sepsis in the laboratory: merging sound science with animal well-being","volume":"58","author":"Nemzek","year":"2008","journal-title":"Comp Med"},{"key":"10.1016\/j.eimce.2020.06.019_bib0350","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.intimp.2016.07.014","article-title":"Stearoyl lysophosphatidylcholine enhances the phagocytic ability of macrophages through the AMP-activated protein kinase\/p38 mitogen activated protein kinase pathway","volume":"39","author":"Quan","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.eimce.2020.06.019_bib0355","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.peptides.2013.10.015","article-title":"An analog of the host-defense peptide hymenochirin-1B with potent broad-spectrum activity against multidrug-resistant bacteria and immunomodulatory properties","volume":"50","author":"Mechkarska","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.eimce.2020.06.019_bib0360","doi-asserted-by":"crossref","first-page":"9541","DOI":"10.1073\/pnas.95.16.9541","article-title":"The peptide antibiotic LL-37\/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface","volume":"8","author":"Bals","year":"1998","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X21002446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X21002446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:15:40Z","timestamp":1783181740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X21002446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2529993X21002446"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2020.06.019","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the immune response modification by lysophosphatidylcholine in the efficacy of antibiotic therapy of experimental models of peritoneal sepsis and pneumonia by Pseudomonas aeruginosa: LPC therapeutic effect in combined therapy","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2020.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}